The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
Mutations in the TP53 gene not only inactivate its tumor suppressor function but also confer this transcription factor with gain-of-function oncogenic properties. A recent paper by Zhu and colleagues reveals a novel molecular pathway driven by mutant p53 and the COMPASS chromatin-modifying complex that is amenable to pharmacological inhibition.